Related Experiment Video
Updated: Jul 2, 2026
10:17
High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
Published on: April 23, 2019
Desvenlafaxine: another "me too" drug?
Michael A Sopko1, Megan J Ehret, Marina Grgas
1Institute of Living at Hartford Hospital, Hartford, CT, USA.
The Annals of Pharmacotherapy
|August 14, 2008
Summary
Desvenlafaxine, an antidepressant, shows similar efficacy and side effects to venlafaxine. Its clinical utility for major depressive disorder appears limited due to comparable outcomes and potential cost-effectiveness issues.
Area of Science:
- Pharmacology and Psychiatry
- Neuroscience
- Clinical Therapeutics
Background:
- Desvenlafaxine is the active metabolite of venlafaxine, a widely used antidepressant.
- Both drugs are serotonin-norepinephrine reuptake inhibitors (SNRIs).
- Understanding the comparative efficacy and safety of desvenlafaxine is crucial for clinical decision-making.
Purpose of the Study:
- To compare the efficacy and safety of desvenlafaxine with its parent drug, venlafaxine.
- To evaluate the clinical utility of desvenlafaxine for treating major depressive disorder.
- To assess potential advantages of desvenlafaxine, such as its interaction with CYP2D6.
Main Methods:
- A comprehensive literature search of MEDLINE and published abstracts was conducted.
- English-language studies and abstracts on desvenlafaxine and venlafaxine were reviewed.
- Human data was prioritized for the analysis.
Main Results:
- Desvenlafaxine demonstrated response and remission rates comparable to venlafaxine in treating major depressive disorder.
- Adverse effect profiles were similar, with common side effects including insomnia, somnolence, dizziness, and nausea.
- Desvenlafaxine may offer an advantage in patients on other CYP2D6-metabolized medications, though cost savings are uncertain.
Conclusions:
- Desvenlafaxine exhibits similar efficacy and safety profiles to venlafaxine.
- The distinct clinical advantages and cost-effectiveness of desvenlafaxine in major depressive disorder appear limited.
- Further research may be needed to establish a definitive role for desvenlafaxine.
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
01:25Antidepressant Drugs: Overview
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
01:26Anxiolytic Drugs: Overview
Anxiolytic drugs are vital in managing anxiety disorders by effectively alleviating symptoms such as excessive fear, tachycardia, and tremors. There are several classes of anxiolytic medications, each with unique mechanisms of action and potential side effects.
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic circuitry.
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic circuitry.
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...